Welcome to our dedicated page for Azenta news (Ticker: AZTA), a resource for investors and traders seeking the latest updates and insights on Azenta stock.
Azenta Inc (Nasdaq: AZTA) is a global leader in life sciences solutions, providing essential tools for drug development, clinical research, and genomic discovery. This page aggregates official press releases and verified news about the company’s advancements in cold-chain sample management, automated storage systems, and multiomics services.
Investors and researchers will find timely updates on Azenta’s operational milestones, including earnings reports, strategic partnerships, product innovations, and industry recognition. The curated content addresses key areas such as sample integrity technologies, genomic data accuracy, and global service expansions.
Key updates include developments from Azenta’s core segments: Life Sciences Products (automated storage solutions, lab consumables) and Life Sciences Services (genomic sequencing, multiomics analytics). Content is organized to help stakeholders track progress in critical research areas like precision medicine and biotherapeutic development.
Bookmark this page for streamlined access to Azenta’s latest announcements, or check regularly for insights into how the company continues to shape the future of life sciences infrastructure and biomedical innovation.
Azenta (Nasdaq: AZTA) announced a Board-approved $250 million share repurchase program.
The program began on Dec 9, 2025 and runs through Dec 31, 2028 unless earlier extended or terminated. Repurchases may be executed via open-market purchases, privately negotiated transactions, or other methods compliant with Rules 10b-18 and 10b5-1. The authorization is discretionary and does not obligate Azenta to buy any specific dollar amount or number of shares; repurchases can be commenced, suspended, modified, or discontinued at any time.
Management said the buyback is part of a capital allocation strategy alongside productivity, organic growth, and disciplined M&A to enhance long-term shareholder value.
Azenta (Nasdaq: AZTA) reported Q4 FY2025 revenue of $159M (+6% YoY; organic +4%) and full‑year revenue of $594M (+4% YoY; organic +3%).
Fiscal 2025 Adjusted EBITDA was $66M with an Adjusted EBITDA margin of 11.2% (up 310 bps YoY). GAAP operating loss was $27M; GAAP diluted EPS from continuing operations was $0.52 and total diluted EPS was ($1.30). Cash and equivalents plus marketable securities totaled $546M.
Guidance for FY2026 calls for organic revenue growth 3–5% and ~300 bps of adjusted EBITDA margin expansion.
Azenta (Nasdaq: AZTA) will release fiscal fourth quarter and full year 2025 results for the period ended September 30, 2025 on Friday, November 21, 2025 before the market opens.
The company will host a live conference call and webcast to discuss results on November 21, 2025 at 8:30 a.m. Eastern Time. Analysts, investors and media can access the live webcast at https://investors.azenta.com/events. A replay will be available beginning 8:30 a.m. ET on November 22, 2025.
Azenta (Nasdaq: AZTA) announced a strategic partnership with the PRECEDE Foundation on Nov 4, 2025 to support early detection of pancreatic cancer by providing secure biorepository storage and streamlined logistics for PRECEDE study samples.
PRECEDE unites more than 60 academic medical centers and maintains the world's largest high-risk patient cohort combining longitudinal clinical data with biospecimen tracking. Pancreatic cancer currently has a five-year survival rate of 13%, and PRECEDE's stated goal is to raise that to 50% within the next decade. Azenta frames the agreement as reinforcing its position in sample management for clinical and diagnostic research and will support PRECEDE ahead of its Annual Meeting in November.
Azenta (Nasdaq: AZTA) will host an Investor Day on Wednesday, December 10, 2025 at its biorepository facility in Indianapolis, Indiana. The event runs 8:30 AM–3:30 PM ET and includes an invite-only morning facility tour plus afternoon executive presentations and Q&A led by John Marotta (CEO) and Lawrence Lin (EVP & CFO).
The afternoon presentations will be webcast beginning at 1:00 PM ET, with a replay available the following day on Azenta's Investor Relations website. In-person attendance is by invitation and requires advanced registration.
Azenta (Nasdaq: AZTA) reported Q3 fiscal 2025 financial results with revenue from continuing operations at $144 million, flat year-over-year with a 2% organic decline. The company's performance showed mixed results across segments, with Multiomics revenue up 4% to $66 million, while Sample Management Solutions declined 4% to $78 million.
Notable improvements include Adjusted EBITDA of $18 million with a margin of 12.3%, up 260 basis points year-over-year, and Non-GAAP Diluted EPS of $0.19, up from $0.14 last year. The company maintains a strong financial position with $565 million in cash and equivalents. Azenta reiterated its fiscal 2025 guidance, expecting 3-5% organic revenue growth and approximately 300 basis points of Adjusted EBITDA margin expansion.
Azenta (Nasdaq: AZTA) has announced a strategic collaboration with Frenova and Nephronomics to advance genomic research in nephrology through the MyReason® genomics research program. The initiative has already registered over 35,000 participants and aims to reach 50,000 participants within two years.
Azenta will provide genomic sequencing through GENEWIZ and manage sample storage in its global biorepository network. Nephronomics, which holds exclusive commercial rights to the MyReason dataset, will utilize AI/machine learning models to analyze the comprehensive cardio-kidney-metabolic (CKM) disease data to identify novel disease subtypes, protective genetic variants, and therapeutic targets.
Fresenius Medical Care (NYSE:FMS) announced a strategic collaboration between its research organization Frenova, Nephronomics, and GENEWIZ by Azenta Life Sciences to advance genomic analysis of kidney disease through the My Reason® genomics program.
The collaboration leverages Frenova's registry of over 35,000 participants (targeting 50,000 in two years) to create the world's largest cardio-kidney-metabolic disease database. GENEWIZ will provide DNA sequencing and biospecimen storage, while Nephronomics holds exclusive commercial rights to develop targeted therapies using AI/ML models.
This initiative aims to transform kidney care through personalized medicine by analyzing genetic mechanisms underlying kidney, cardiovascular, and metabolic diseases.
Azenta (Nasdaq: AZTA) announced its participation in the upcoming 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference. The company's management team will attend the virtual event scheduled for Tuesday, August 12, 2025. This conference provides an opportunity for investors and analysts to engage with Azenta's leadership through one-on-one meetings.
Azenta (Nasdaq: AZTA) has scheduled its fiscal third quarter 2025 earnings announcement for Tuesday, August 5, 2025, before market opening. The company will host a conference call and webcast at 8:30 a.m. Eastern Time on the same day to discuss the financial results for the quarter ended June 30, 2025.
Stakeholders can access the live webcast through the company's investor relations website. A replay of the event will become available starting at 8:30 a.m. ET on August 6, 2025.
FAQ
What is the current stock price of Azenta (AZTA)?
What is the market cap of Azenta (AZTA)?
